Navigation Links
Treatment Algorithm Helps Successfully Manage Diabetes after Transplant Surgery
Date:4/16/2009

HOUSTON, April 16 /PRNewswire-USNewswire/ -- New research highlighting the relationship between steroids and insulin requirements suggests a possible treatment algorithm in post-liver transplant patients. This research will be presented on May 15, 2009 at the American Association of Clinical Endocrinologists (AACE) 18th Annual Meeting & Clinical Congress in Houston, Texas.

(Logo: http://www.newscom.com/cgi-bin/prnh/20090324/DC88061LOGO-b)

The tentative algorithm was developed as doctors tried to understand the elevation in blood sugar levels in patients that received post-operative steroids due to a liver transplant. The blood sugar rise was attributed to the toxic effects of steroid medications on beta cell function.

Additionally, the relationship between prolonged exposure to steroids generally six months revealed a strong relationship with persistent diabetes at a one year follow up after transplantation

"It appears that these steroids can lead to a permanent diabetic state," Umadevi Muthyala, M.D., said. "Prevention strategies must be considered in environments where they are commonly used."

Muthyala's team developed a tentative dosing algorithm to account for the increased insulin need in relation to steroid dosage.

"Although the data is not definitive, it gives us a handle on proper dosing and can be used to prospectively study other populations," she said.

Also at the 2009 AACE 18th Annual Meeting & Clinical Congress, diabetes experts will analyze the NICE-SUGAR study's impact on inpatient glycemic control. Other topics of interest include a look at the wide ranging impact of Vitamin D in the human body, and clinical recommendations for the treatment of prediabetes -- America's largest healthcare epidemic.

Media Registration

Media Registration for the AACE 18th Annual Meeting & Clinical Congress is available free of charge to members of the working media online here. Additional press releases concerning the meeting are available online here.

About AACE

AACE is a professional medical organization with more than 6,200 members in the United States and 92 other countries. Founded in 1991, AACE is dedicated to the optimal care of patients with endocrine problems. AACE initiatives inform the public about endocrine disorders. AACE also conducts continuing education programs for clinical endocrinologists, physicians whose advanced, specialized training enables them to be experts in the care of endocrine disease, such as diabetes, thyroid disorders, growth hormone deficiency, osteoporosis, cholesterol disorders, hypertension and obesity.

About the AACE Annual Meeting

The 18th Annual Meeting & Clinical Congress will be held in Houston, Texas on May 13-17 at the George R. Brown Convention Center, Hilton Americas Houston. The AACE Annual Meeting & Clinical Congress is structured to provide relevant clinical information for the practicing endocrinologist. The programs will focus on information that allows endocrinologists to achieve the best solutions for the diagnosis and management of endocrine diseases. Pertinent scientific, clinical practice and patient management will be disseminated via general sessions, workshops, meet-the-experts and satellite symposia.


'/>"/>
SOURCE American Association of Clinical Endocrinologists
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Dense Breasts Complicate Testing and Treatment
2. Medifocus Inc. Reports Improved Clinical Efficacy for its Phase II, Randomized Clinical Study for the Treatment of Early Stage Breast Cancer Tumors
3. Do patients at risk for B-cell malignancy need antiviral treatment?
4. Non-drug treatment of Alzheimers disease: Long-term benefit not proven
5. Ocean Cosmetic Medicine of Santa Monica Has Created Something New: Personalized Boutique Style Aesthetic Treatments
6. Melatonin is an effective treatment for sleep problems in children with autism
7. Mylan Confirms First-to-File Patent Challenge Relating to Xeloda(R) Cancer Treatment
8. Medarex to Receive Milestone Payment for Approval of SIMPONI(TM) for the Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
9. Singapore First in Southeast Asia to Use Novel Treatment for Sports and Musculoskeletal Injuries
10. Ex-White House Drug Czar McCaffrey, U.S. Congress Drug Caucus Chair Cummings, CRC Health CEO Karlin Join Hopkins Researchers at News Conference April 17 on Breakthrough Study: Internet Video Drug Treatment as Effective as Traditional Counseling
11. Blacks Less Likely to Get Optimal Lung Cancer Treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... ... , ... Harris Communications, Inc., a leading provider of assistive technology for ... Deaf Seniors of America Conference, April 4-7 at the Hotel Westin Galleria in Houston. ... staff from Harris Communications and to try out the newest assistive devices available to ...
(Date:3/25/2017)... ... , ... Getting earned media coverage meaningful for Garden Media Group's clients is ... year, Garden Media aims to provide material helpful to clients’ goals and bottom lines. ... key messages to gain coveted media placements, Garden Media wows clients year-round. , ...
(Date:3/24/2017)... (PRWEB) , ... March 24, 2017 , ... ... solutions for contaminated soil, dredged material, and hazardous and non-hazardous materials announced today ... Allentown, Pennsylvania. This acquisition will add four additional processing facilities and a ...
(Date:3/24/2017)... ... March 24, 2017 , ... Mediaplanet today ... conversation on the current obstacles facing infection prevention and offer strategies for the ... by these infections. , The print component of “Fighting Infection” is distributed ...
(Date:3/24/2017)... ... March 24, 2017 , ... Digital Scientists, a software innovation lab specializing in ... a Greenville, South Carolina location. The lab has set up shop at ... been working with South Carolina clients for years from our office here in Atlanta,” ...
Breaking Medicine News(10 mins):
(Date:3/27/2017)... and BOSTON , March 27, ... global pharmaceutical company and Paratek Pharmaceuticals, Inc. (Nasdaq: ... and commercialization of innovative therapies based upon tetracycline ... of sarecycline for the treatment of moderate to ... endpoints. Sarecycline is a once-daily, oral, narrow spectrum ...
(Date:3/27/2017)... 27, 2017  PhaseRx, Inc. (NASDAQ: PZRX), a ... liver diseases in children, today reported financial results ... December 31, 2016 and provided an update on ... to make progress during the fourth quarter of ... our non-human primate safety study, and with our lead ...
(Date:3/24/2017)... , Mar 24, 2017 Research ... Therapy Manufacturing Market, 2017-2027" report to their offering. ... The Cell ... the rapidly growing market of cell therapy manufacturing and focuses ... manufacturing facilities. These therapies are anticipated to emerge as viable ...
Breaking Medicine Technology: